Pfizer's COVID

The decline in community and Pax Levid combined this year from last year could be $32 billion. That's worse than the consensus estimate, which puts the decline at $25 billion. Merck later this decade will face a key patent expiration of its own. Jeff downgraded Pfizer stock to neutral from buy this past week. And he did just the opposite with Merck upgrading it to buy.